BioLineRx receives U.

There exists a significantly now longer amount of exclusivity to your lead item, which reflects substantial additional improvement in its advancement towards commercialization. This approval, with recent additional patent collectively approvals regarding BL-1020 and other drug applicants, can be a testament to our focused and extremely professional patent application technique, stated Dr. Kinneret Savitsky, CEO of BioLineRx. We think that the market prospect of BL-1020 has increased in the last several months, as some bigger pharmaceutical companies have got reported failures during late-stage scientific trials, or have decreased the operations surrounding their schizophrenia therapies because of lack of patent protection.Catharines on September 16, 2014 and will be the first of its kind to use with zero patient costs. With the recent execution of the Marihuana for Medical Purposes Rules , medical marijuana has become a legitimate treatment choice for many Canadians. However, most doctors with experience in this field charge up to $400 each year for a prescription or other mandatory providers. ‘Medical marijuana gets the potential to boost the lives of so many Canadians,’ said Joseph del Moral, Director of Canadian Cannabis Clinics. ‘However the costs becoming imposed by clinics specializing in this field are placing it out of grab many. With the starting of the clinic, and future places, we are making medical marijuana even more accessible to those sufferers considering it as a treatment choice.’ Related StoriesNew review finds scant scientific proof supporting usage of cannabinoids in rheumatic diseasesEndocannabinoids can affect development of baby's pancreasDigiPath Labs, Romer Labs to validate kit-based assays for food-borne pathogen, mycotoxin tests for cannabisCanadian Cannabis Clinics has also partnered with Canada's leading medical marijuana counselling and resource service, CanvasRx, to teach and inform individuals about medical cannabis choices.